Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide

British Journal of Pharmacology

Volumn 153, Issue 7, 2008, Pages 1579-1586

  Xu, H ^a   Williams, K M ^b   Liauw, W S ^b   Murray, M ^a   Day, R O ^b   McLachlan, A J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

CYP2C9; Genotype; Gliclazide; Pharmacodynamics; Pharmacokinetics; St. John's wort

Indexed keywords

CYTOCHROME P450 2C9; GLICLAZIDE; HYPERICUM PERFORATUM EXTRACT;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HYPERICUM PERFORATUM; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; GENOTYPE; GLICLAZIDE; HALF-LIFE; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PLANT EXTRACTS; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING;

EID: 41649113326     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707685     Document Type: Article

References (41)

1. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH et al. (2003). Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 55: 203-211.
2. Campbell DB, Adriaenssens P, Hopkins YW, Gordon B, Williams JRB (1980). Pharmacokinetics and metabolism of gliclazide: a review. In: Keen et al. (eds), Gliclazide and the Treatment of Diabetes, International Congress and Symposium Series No. 20. pp 71-82, London: Academic Press and Royal Society of Medicine.
3. Campbell DB, Lavielle R, Nathan C (1991). The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract 14: S21-S36.
4. Chen Y, Ferguson SS, Negishi M, Goldstein JA (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308: 495-501.
5. Davis TME, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ et al. (2000). Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol 49: 223-230.
6. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB (2003). Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73: 41-50.
7. Elbein SC, Sun J, Scroggin E, Teng K, Hasstedt SJ (2001). Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and epatocyte nuclear factor 1alpha genes. Diabetes Care 24: 472-478.
8. Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS et al. (2007). Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 64: 450-457.
9. Goksel DL, Fischbach K, Duggirala R, Mitchell BD, Aguilar-Bryan L, Blangero J et al. (1998). Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet 103: 280-285.
10. Holstein A, Plaschke A, Ptak M, Egberts E, El-Din J, Brockmoller J et al. (2005). Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60: 103-106.
11. Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK (1998). Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release 51: 185-192.
12. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC et al. (2004). Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57: 592-599.
13. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999). Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9: 71-80.
14. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C et al. (2002a). Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12: 101-109.
15. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C et al. (2002b). Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71: 286-296.
16. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J (2005). Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44: 1209-1225.
17. Kristoffersen S, Atkin P, Shenfield G (1996). Uptake of alternative medicine. Lancet 347: 972.
18. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL (1998). Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353: 16-28.
19. Lee CR, Goldstein JA, Pieper JA (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12: 251-263.
20. Lupo B, Bataille D (1987). A binding site for [3H]glipizide in the rat cerebral cortex. Eur J Pharmacol 140: 157-169.
21. MacLennan AH, Myers SP, Taylor AW (2006). The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 184: 27-31.
22. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B et al. (2004). Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 76: 330-340.
23. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004). Interaction of St John's wort with conventional drugs: systematic review of clinical trials. Br Med J 329: 27-30.
24. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al. (2000). St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500-7502.
25. Oida T, Yoshida K, Kagemoto A, Sekine Y, Higashijima T (1985). The metabolism of gliclazide in man. Xenobiotica 15: 87-96.
26. Park JY, Kim KA, Kim SL, Park PW (2004). Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects. J Pharm Biomed Anal 35: 943-949.
27. Park JY, Kim KA, Park PW, Park CW, Shin JG (2003). Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 74: 334-340.
28. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000). Indinavir concentrations and St John's wort. Lancet 355: 547-548.
29. Ryan EA, Pick ME, Marceau C (2001). Use of alternative medicines in diabetes mellitus. Diabet Med 18: 242-245.
30. Shaw KM (2006). Overcoming the hurdles to achieving glycemic control. Metabolism 55: 6S-9S.
31. Shima K, Ikegami H, Tanaka A, Ezaki A, Kumahara Y (1982). Effect of dietary fiber, konjac mannan and guar gum, on absorption of sulfonylurea in man. Nutr Rep Int 26: 297-302.
32. Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H et al. (2004). CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 74: 827-834.
33. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K et al. (2001). Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518-524.
34. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. (1996). The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349.
35. Taylor AR, Brownsill RD, Grandon H, Lefoulon F, Petit A, Luijten W et al. (1996). Synthesis of putative metabolites and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4- methylphenylsulfonyl) urea], in diabetic patients. Drug Metab Dispos 24: 55-64.
36. Topic E, Stefanovic M, Samardzija M (2004). Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin Chem Lab Med 42: 72-78.
37. Wang H, Craig RL, Schay J, Chu W, Das SK, Zhang Z et al. (2004). Alpha-endosulfine, a positional and functional candidate gene for type 2 diabetes: molecular screening, association studies, and role in reduced insulin secretion. Mol Genet Metab 81: 9-15.
38. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001). The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70: 317-326.
39. Wester MR, Lasker JM, Johnson EF, Raucy JL (2000). CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28: 354-359.
40. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J et al. (2001). Comparison of German St John's wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash) 41: 560-566.
41. Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H et al. (2007). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 64: 67-74.